Compare Msci Inc (MSCI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Msci Inc trades at $554.53 (market cap $40.09B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× Msci Inc's market cap, and Msci Inc pays a 1.49% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| MSCI | VRTX | |
|---|---|---|
Market Cap | $40.09B | $134.06B |
Sector | Financials | Health |
52-Week High | $643.83 | $557.96 |
52-Week Low | $511.84 | $376.62 |
Enterprise Value | $46.25B | $128.18B |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $551.39, down 3.77% over 24 hours amid a bearish technical signal. The stock shows strong fundamentals with a 40.73% net income margin and consistent revenue growth, reaching $3.13B in 2025. Recent Q2 2026 earnings slightly missed expectations, but the company maintains robust profitability and a $2.05 dividend. Analyst consensus is bullish with a $728.14 price target, though technical indicators suggest near-term pressure with support at $545.
Outlook remains positive driven by high-margin recurring revenue and strategic acquisitions like First Street. Risks include elevated debt levels and market sensitivity. Institutional sentiment is strong with 73% buy ratings, positioning MSCI for long-term growth despite current technical weakness.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
